← Back to Clinical Trials
Recruiting NCT06306963

NCT06306963 Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06306963
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Gastric Antral Vascular Ectasia
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2024-03-22
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Gastric Emptying Breath Test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2024-03-22 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this study, you will help us learn how often these symptoms occur and how they relate to stomach functioning.

Eligibility Criteria

Inclusion Criteria: * Patients \>18 years of age with endoscopic evidence of Gastric Antral Vascular Ectasia. * Willingness to participate in the study * Capacity to provide informed consent. * No evidence of organic, systemic, or metabolic disease (e.g. diabetes mellitus) to explain the symptoms on routine investigations Exclusion Criteria: * Patients with transfusion dependent blood loss. * Patients with severe decompensated liver disease. * Patients with end stage renal disease. * Presence of other diseases (structural or metabolic) which could interfere with interpretation of the study results. * Pregnant or lactating women. * Patients who have not had a CBC and differential blood draw completed within the last six months. * Current heavy alcohol use.

Contact & Investigator

Central Contact

Taylor N Hines

✉ hines.taylor@mayo.edu

📞 507-538-9959

Principal Investigator

Xiao Jing Wang, MD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT06306963 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Gastric Antral Vascular Ectasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06306963 currently recruiting?

Yes, NCT06306963 is actively recruiting participants. Contact the research team at hines.taylor@mayo.edu for enrollment information.

Where is the NCT06306963 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT06306963 clinical trial?

NCT06306963 is sponsored by Mayo Clinic. The principal investigator is Xiao Jing Wang, MD at Mayo Clinic. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology